ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).

被引：0
作者：
Lonial, Sagar
Richardson, Paul Gerard Guy
Moreau, Philippe
Orlowski, Robert Z.
San-Miguel, Jesus F.
Dimopoulos, Meletios A.
Palumbo, Antonio Pierangelo
Facon, Thierry
Vij, Ravi
White, Darrell
Reece, Donna Ellen
Singhal, Anil
Kroog, Glenn Scott
Kopit, Justin
Anderson, Kenneth Carl
机构：
[1] Multiple Myeloma Res Consortium, Norwalk, CT USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Hosp, Nantes, France
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Hosp Univ Salamanca, Salamanca, Spain
[7] Hellen Cooperat Oncol Grp, Athens, Greece
[8] Univ Turin, Turin, Italy
[9] Hop Claude Huriez, Lille, France
[10] Washington Univ, Sch Med, St Louis, MO USA
[11] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[12] Princess Margaret Hosp, Program Multiple Myeloma, Toronto, ON M4X 1K9, Canada
[13] Abbott Biotherapeut, Redwood City, CA USA
[14] Bristol Myers Squibb Co, Global Clin Res Oncol, Princeton, NJ USA
[15] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8112
引用
收藏
页数：1
相关论文
共 50 条
[31]   Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN plus DEX) versus LEN plus DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis. [J].
Obeng-Kusi, Mavis ;
Arku, Daniel ;
Alrawashdh, Neda ;
Choi, Briana ;
Alkhatib, Nimer S. ;
McBride, Ali ;
Abraham, Ivo .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32]   PHASE (PH) I/II STUDY OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE (LEN/DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM): UPDATED PH II RESULTS AND PH I/II LONG TERM SAFETY [J].
Facon, T. ;
Richardson, P. ;
Jagannath, S. ;
Moreau, P. ;
Jakubowiak, A. ;
Raab, M. ;
Vij, R. ;
White, D. ;
Reece, D. ;
Benboubker, L. ;
Zonder, J. ;
Deng, W. ;
Bleickardt, E. ;
Singhal, A. ;
Lonial, S. .
HAEMATOLOGICA, 2013, 98 :319-319
[33]   Phase 1 open-label study of panobinostat, lenalidomide, bortezomib plus dexamethasone in relapsed and relapsed/refractory multiple myeloma [J].
Laubach, Jacob P. ;
Tuchman, Sascha A. ;
Rosenblatt, Jacalyn M. ;
Mitsiades, Constantine S. ;
Colson, Kathleen ;
Masone, Kelly ;
Warren, Diane ;
Redd, Robert A. ;
Grayson, Dena ;
Richardson, Paul G. .
BLOOD CANCER JOURNAL, 2021, 11 (02)
[34]   Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis [J].
Mateos, Maria-Victoria ;
Lopez-Corral, Lucia ;
Hernandez, Miguel T. ;
de la Rubia, Javier ;
Jose Lahuerta, Juan ;
Giraldo, Pilar ;
Bargay, Joan ;
Rosinol, Laura ;
Oriol, Albert ;
Garcia-Larana, Jose ;
Palomera, Luis ;
de Arriba, Felipe ;
Prosper, Felipe ;
Martino, Mariluz ;
Teruel, Ana-Isabel ;
Hernandez, Jose ;
Esteves, Graca ;
Mariz, Mario ;
Alegre, Adrian ;
Guzman, J. L. ;
Quintana, Nuria ;
Garcia, Jose-Luis ;
San-Miguel, Jesus F. .
BLOOD, 2009, 114 (22) :254-254
[35]   LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM) [J].
Weisel, Katja ;
Hungria, Vania ;
Quach, Hang ;
Yoon, Sung-Soo ;
Rodriguez-Otero, Paula ;
Sinha, Arijit ;
Boyapati, Anita ;
Lyon, Charlotte ;
Moore, Vygngley ;
Inocencio, Tim ;
Harnett, James ;
Chi, Lei ;
Lorenc, Karen Rodriguez ;
Kroog, Glenn ;
Voorhees, Peter .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 :S63-S64
[36]   A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA [J].
Moreau, P. ;
Richardson, P. ;
Jakubowiak, A. ;
Jagannath, S. ;
Raab, M. ;
Facon, T. ;
Vij, R. ;
Reece, D. ;
White, D. ;
Benboubker, L. ;
Zonder, J. ;
Rossi, J. F. ;
Tsao, C. ;
Parli, T. ;
Kroog, G. ;
Singhal, A. ;
Lonial, S. .
HAEMATOLOGICA, 2012, 97 :474-474
[37]   A PHASE III RANDOMIZED, OPEN-LABEL STUDY OF ISATUXIMAB (SAR650984) PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS POM AND DEX IN RELAPSED/REFRACTORY MULTIPLE MYELOMA [J].
Richardson, P. ;
Attal, M. ;
San Miguel, J. ;
Campana, F. ;
Le-Guennec, S. ;
Hui, A. -M. ;
Risse, M. -L. ;
Anderson, K. .
HAEMATOLOGICA, 2017, 102 :779-779
[38]   A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma. [J].
Richardson, Paul G. ;
Attal, Michel ;
Miguel, Jesus San ;
Campana, Frank ;
Le-Guennec, Solenn ;
Hui, Ai-Min ;
Risse, Marie-Laure ;
Anderson, Kenneth Carl .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[39]   A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial [J].
Jian Hou ;
Xin Du ;
Jie Jin ;
Zhen Cai ;
Fangping Chen ;
Dao-bin Zhou ;
Li Yu ;
Xiaoyan Ke ;
Xiao Li ;
Depei Wu ;
Fanyi Meng ;
Huisheng Ai ;
Jingshan Zhang ;
Honeylet Wortman-Vayn ;
Nianhang Chen ;
Jay Mei ;
Jianmin Wang .
Journal of Hematology & Oncology, 6
[40]   A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial [J].
Hou, Jian ;
Du, Xin ;
Jin, Jie ;
Cai, Zhen ;
Chen, Fangping ;
Zhou, Dao-bin ;
Yu, Li ;
Ke, Xiaoyan ;
Li, Xiao ;
Wu, Depei ;
Meng, Fanyi ;
Ai, Huisheng ;
Zhang, Jingshan ;
Wortman-Vayn, Honeylet ;
Chen, Nianhang ;
Mei, Jay ;
Wang, Jianmin .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
12345